Clearstone expands in Asia through Mitsubishi partnership

By Gareth Macdonald

- Last updated on GMT

Related tags Contract research organization Clinical trial Clearstone

Contract research organisation (CRO) Clearstone Central Laboratories has unveiled a ‘preferred provider’ partnership with Mitsubishi Chemical Medience (MCM), continuing its efforts to expand in Asia.

The deal grants Canada-headquartered Clearstone access to MCM’s 21-strong network of contract clinical and diagnostic laboratory facilities that extends across Japan.

In return, MCM and its customers will be able to use the Canadian CRO’s global laboratory facilities, including its recently expanded lab in Beijing, China and its unit in Singapore.

Spokesman Bernie Clark told Outsourcing-pharma.com that: “Clearstone has been working with Mitsubishi over the last year in a similar fashion and we are now at a point where we can publicly announce the partnership​,” adding that the deal stands to benefit both parties.

He went on to explain that while Clearstone does not have any lab facilities in Japan, it does service a large number of trial sites in the country and added that access to MCM’s labs will provide customers with more options.

The MCM deal is also similar to an agreement Clearstone formed with Lab Corp’s Esoterix Clinical Trial Services unit late last year, which granted the latter firm access to the Beijing​ laboratory.

Asia partnering

More broadly the new partnership, financial terms of which have not been disclosed, is in keeping with the global expansion strategy Clearstone set out for 2011.

In February the Canada-headquartered CRO said that its plan was to build its presence in the Asia-Pacific region through the formation of strategic partnerships with local players.

Clark confirmed that this is still the case even after the MCM partnership, telling Outsourcing-pharma.com the firm “will continue to look for unique and innovative solutions and relationships that help our clients streamline and accelerate their clinical research programs​.”

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more